Keytruda for Non-Small Cell Lung Cancer (Second Line or Beyond) – Details


( Last Updated : November 18, 2016)
Generic Name:
Pembrolizumab
Project Status:
Complete
Therapeutic Area:
Non-Small Cell Lung Cancer
Manufacturer:
Merck Canada Inc.
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0077-000
NOC Status at Filing:
Post NOC
NOC Date:

Details


Strength:
50mg vial
Tumour Type:
Lung
Indications:
Non-Small Cell Lung Cancer (Second Line or Beyond)
Funding Request:
For the treatment of patients with metastatic NSCLC whose tumours express PD-L1 (as determined by a validated test) and who have disease progression on or after platinum-containing chemotherapy. Funding is being requested for patients with a TPS (Tumour Proportion Score) of PD-L1 ≥1%.
Sponsor:
Merck Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.